Harmony Biosciences Holdings, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Harmony reported Q3 2026 WAKIX net revenue of $268.9M (12% YoY growth) with 400 net patient adds reaching 9,350 average patients; the company reiterates full-year guidance of $1.0B–$1.04B. BP-205 multiple-ascending dose study showed favorable safety and tolerability over 14 days of once-daily dosing with no serious adverse events, liver, or visual issues. CEO Jeffrey Dayno will retire December 31, 2026, succeeded by COO Peter Anastasiou effective January 1, 2027.
Why this rating
Solid Q3 execution and confirmed guidance show core business health; BP-205 data supportive but still early-stage Phase 1b; leadership transition planned and orderly. Modest revenue growth relative to $1.3B market cap; no material M&A or strategic pivots announced.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.